LSPG(SZ:301111)2025-04-25 11:25Financial Performance - The company's operating revenue for 2024 was ¥278,638,789.67, a decrease of 4.71% compared to ¥292,397,132.03 in 2023[18]. - The net profit attributable to shareholders for 2024 was ¥4,162,684.65, representing a significant decline of 87.57% from ¥33,501,697.88 in 2023[18]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥6,532,207.68 in 2024, a decrease of 127.65% compared to ¥23,623,155.29 in 2023[18]. - The cash flow from operating activities for 2024 was ¥3,208,543.56, a turnaround from -¥12,799,223.82 in 2023, marking an increase of 125.07%[18]. - The total assets at the end of 2024 were ¥933,166,569.41, reflecting a growth of 9.07% from ¥855,535,468.09 at the end of 2023[18]. - The basic earnings per share for 2024 were ¥0.03, down 85.71% from ¥0.21 in 2023[18]. - In 2024, the company achieved operating revenue of 27,863.88 million yuan, a decrease of 1,375.83 million yuan or 4.71% year-on-year[41]. - The net profit attributable to shareholders was 416.27 million yuan, down 2,933.90 million yuan or 87.57% year-on-year; the net profit after deducting non-recurring gains and losses was -653.22 million yuan, a decrease of 3,015.54 million yuan or 127.65% year-on-year[41]. Dividend Distribution - The company plans to distribute a cash dividend of 0.50 RMB per 10 shares to all shareholders, based on a total of 160,000,000 shares[6]. - The annual cash dividend proposal for 2024 is set at 0.5 yuan per 10 shares, totaling 8,000,000 yuan (including tax) for 160,000,000 shares[135]. - The company has maintained a stable profit distribution policy, ensuring reasonable returns to investors[132]. - There are no plans for stock dividends or capital reserve transfers in the current profit distribution proposal[135]. Business Strategy and Development - The company is focusing on the traditional Chinese medicine sector, leveraging its unique advantages in chronic disease prevention and health management[28]. - The company aims to enhance the quality and innovation of traditional Chinese medicine through new regulatory guidelines and digital transformation initiatives[30]. - The company is focusing on developing a health ecosystem covering prevention, diagnosis, and rehabilitation through three main business segments: traditional Chinese medicine, medical services, and health management[33]. - The company is actively pursuing new product development and market strategies through its various healthcare investments[74]. - The company is developing functional health foods based on the concept of "medicinal food homology," with a focus on high-end nourishing products sourced from Southeast Asia[93]. - The healthcare services segment will focus on a comprehensive life-cycle health management model, integrating prevention, diagnosis, rehabilitation, and health maintenance services[93]. Market and Industry Trends - The national strategy continues to promote the development of traditional Chinese medicine, aiming for a trillion-level health industry by 2030[28]. - The pharmaceutical industry in China achieved a revenue of CNY 29,762.7 billion, remaining flat year-on-year, while profits decreased by 0.9% to CNY 4,050.9 billion[29]. - The traditional Chinese medicine sector saw a decline in revenue and profit by 2.3% and 0.2% respectively[29]. - The company is positioned to benefit from policy incentives and market demand, driving the industry towards standardization and internationalization[28]. Risk Management - The management has highlighted potential risks and corresponding measures in the future development outlook section[5]. - The company faces risks in expanding its healthcare services due to the time required for market cultivation, which may impact short-term profitability[94]. - The company is exposed to risks related to the supply and price volatility of raw materials, particularly Chinese medicinal herbs, which could impact profitability[95]. - The company will strengthen research and analysis of the upstream Chinese medicinal materials market to effectively reduce risks related to raw material supply and price fluctuations[96]. Corporate Governance - The board of directors consists of 7 members, including 3 independent directors, ensuring compliance with legal and regulatory requirements[102]. - The company has a dedicated audit committee responsible for overseeing internal control systems and the authenticity of financial information[105]. - The company actively engages with investors through various platforms, ensuring transparency and protecting the rights of minority shareholders[103]. - The company has established a comprehensive internal control system to improve governance and operational efficiency[101]. - The company has committed to maintaining a high level of information disclosure, ensuring that all shareholders have equal access to company information[103]. Environmental Responsibility - The company holds a pollution discharge permit valid from August 25, 2023, to August 24, 2028, for various manufacturing activities[142]. - The company complies with the wastewater discharge standards, with CODcr levels at 89 mg/L, which is below the limit of 100 mg/L[143]. - The company has implemented measures to ensure that ammonia nitrogen levels in wastewater do not exceed the standard of 8 mg/L[143]. - The company has not reported any instances of exceeding pollution discharge limits during the reporting period[143]. - The company has invested CNY 523,500 in environmental governance and protection during the reporting period[146]. Employee Management - The company reported a total of 667 employees at the end of the reporting period, with 292 in the parent company and 375 in major subsidiaries[128]. - The employee composition includes 147 production staff, 224 sales personnel, 57 technical staff, 27 financial staff, and 212 administrative staff[128]. - The company has established a performance evaluation system linking employee salaries to company performance and key performance indicators[129]. - The company has conducted training programs focusing on new employee onboarding, GMP training, and management skills development[130]. Investment and Acquisitions - The company invested 680 million yuan to acquire 85% of Guangdong Tongren Pharmaceutical Co., Ltd., enhancing its capabilities in the Chinese herbal medicine and herbal pieces business[43]. - The company acquired 85% of Guangdong Wannianqing Pharmaceutical Co., Ltd. for 6.8 million yuan and has completed the business registration change[137]. - The company also acquired 51% of Hainan Wanmitang Pharmaceutical Co., Ltd. for 1.53 million yuan, but the business registration change has not yet been completed[137]. - The company has cumulatively used CNY 36,970.81 million of the raised funds, representing 84.02% of the total amount raised[81]. Shareholder Relations - The participation rate of investors in the 2024 first extraordinary general meeting was 56.18%[108]. - The participation rate of investors in the 2023 annual general meeting was 56.17%[109]. - The company has a total of 13,167 ordinary shareholders at the end of the reporting period, a decrease from 13,374 at the end of the previous month[200]. - The company has a total of 5 shareholders holding more than 5% of the shares, with the largest shareholder being Guangdong Jino Health Technology Co., Ltd.[200].